BackyardProduction A new study has found that Novo Nordisk's ( NVO ) GLP-1 for type 2 diabetes, Ozempic (semaglutide), may have a surprising additional benefit: It may reduce the risk of opioid overdoses. A new study found that when compared to other diabetes.
Back to Health Page
